-
Re-Introducing Nuts in Allergic Patients
This study aims to compare the safety and the compliance to different procedures (A: at home or B: at the hospital) for introducing tree nuts into the diet of patients with Immunoglobulin E (IgE)-mediated allergy to the aforementioned nuts. In parallel, the effectiveness of tree nuts' introduction in respect to tolerance induction compared to the standard care (strict avoidance of tree nuts) will be evaluated.
-
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic criteria. The Secondary objectives are: - To demonstrate the efficacy of dupilumab compared to placebo in pediatric patients with active EoE after 16 weeks of treatment as assessed by endoscopic visual measurements of disease activity using the Eosinophilic Esophagitis-Endoscopic Reference Score (EoE-EREFS) and histologic abnormalities as measured by the EoE Histology Scoring System ...
-
Synbiotic Extensively Hydrolysed Feed Study
This study of the tolerance and acceptability of a extensively hydrolysed formula (eHF) containing pre- and probiotics will assess gastrointestinal (GI) tolerance, product intake and acceptability in 40 infants (aged <13 months) currently using or requiring an extensively hydrolysed formula for the dietary management of CMA. Patients already prescribed an eHF (or other appropriate feed for CMA) at time of recruitment will undertake a 3 day baseline period in which their current symptoms, compliance, GI tolerance and acceptability towards their current feed is assessed, before introducing the study product for a period of 4 weeks. ...
-
The Incidence of Venous Thromboembolism in Atopic Dermatitis
This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.
-
The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants
This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants. A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.
-
the Relationship Between Allergic Rhinitis and the Risk of Symptom in Patients With Mild COVID-19
At present, most studies mainly focussed on severe patients, and there was no comparison of symptom differences between AR patients and healthy people with mild infection to evaluate the symptoms of AR patients during infection and to provide preventive treatment in advance. So this experiment was designed.
-
Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus
The goal of this study is to test the feasibility and the tolerability of a tethered spectrally encoded confocal microscopy (SECM) capsule and to use it to image the esophagus.
-
Compassionate Use of Dupilumab
Provide Compassionate Use of Dupilumab
-
Expanded Access Protocol for Patients With Eosinophilic Esophagitis
This expanded access program is an open-label, single-arm design where consenting patients may participate up until APT-1011 is commercially available in the relevant regions or the protocol is terminated by the Sponsor.
-
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
This is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.
Take Action
Join over 10,000 individuals and families managing food allergies who are sharing their food allergy stories and making a critical difference, helping to speed the search for new treatments and informing life-changing improvements in patient care.
Donate
You can help improve 32 million lives by supporting Food Allergy Research & Education (FARE) with your tax-deductible gift today.
221 - 230 of 230 Trials
